Scott A. Small believes the key in leading scientists down a new pathway for drug discovery may be in targeting a biological mechanism in the cell called retromer endosomal dysfunction.

In October 2017, renowned neuro-oncologist Howard A. Fine, was awarded a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

At the Eleanor and Lou Gehrig ALS Center at NewYork-Presbyterian/Columbia, clinicians and scientists are leading efforts to combat amyotrophic lateral sclerosis and other motor neuron diseases.

A NewYork-Presbyterian/Weill Cornell neurosurgeon is redefining treatment of essential tremor, as the first in New York to offer high-intensity focused ultrasound to treat the brain disorder.

Over the past three decades, Dr. Manikkam Suthanthiran and his colleagues at NewYork-Presbyterian/Weill Cornell is responsible for much of the progress in kidney transplantation.

NewYork-Presbyterian/Columbia, a Kidney Precision Medicine Project recruitment site, is working to understand the cell types that are specific to kidney injury and can be targeted with new therapeutic agents.

Clinicians and researchers brought the important issue of caregiver burden to the fore and are seeking ways to not only identify and assess caregivers’ needs, but also to provide interventions to support them.

A physician-scientist at NewYork-Presbyterian/Columbia has set her sights on applying the discoveries made in her lab to improve tissue healing and treatment for the many diseases that can affect the gut.